" class="no-js "lang="en-US"> Epic Sciences - Medtech Alert
Tuesday, April 16, 2024
Epic Sciences | Pharmtech Focus

Epic Sciences

About Epic Sciences

Epic Sciences

Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic’s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic’s goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians with real-time information to guide treatment choices.

Related Story

Epic Sciences Raises $24M in Series G Financing to Continue Funding Commercialization of DefineMBC

April 14 2023

Epic Sciences, a privately held diagnostics company, has completed a $24 million Series G which […]

Epic Sciences Raises $43M in First Close of Series F Financing to Advance Comprehensive Profiling for Metastatic Cancer Patients

June 6 2022

Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $43 […]

Epic Sciences and Biosplice Therapeutics Announce Partnership for Metastatic Cancer Trials

January 28 2022

Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for […]